Maintenance Therapy for Stage IV Lung Adenocarcinoma

Patient Selection and Treatment Rationale

• The American Society of Clinical Oncology (ASCO) recommends maintenance therapy with pembrolizumab plus pemetrexed following initial combination therapy with platinum, pemetrexed, and pembrolizumab for patients with non-squamous NSCLC, including those with stage IV lung adenocarcinoma 1
• For patients with non-squamous NSCLC without driver alterations and PD-L1 <1%, pembrolizumab plus platinum-based chemotherapy is an appropriate treatment option, as recommended by the American Society of Clinical Oncology (ASCO) 1
• The European Society for Medical Oncology (ESMO) guidelines support the use of platinum-based doublets containing a third-generation cytotoxic drug, such as pemetrexed, for advanced NSCLC 3

Treatment Duration and Monitoring

• Standard practice is to continue maintenance therapy until disease progression or unacceptable toxicity, according to the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) 3, 4
• The patient's ECOG PS is listed as 1-2, which is borderline for combination therapy, but careful monitoring for toxicity is warranted given the borderline performance status, as recommended by the American Society of Clinical Oncology (ASCO) 2

Histology Considerations

• Pemetrexed has demonstrated superior efficacy specifically in non-squamous histology, including adenocarcinoma, according to the European Society for Medical Oncology (ESMO) 4
• The combination of platinum-based chemotherapy with pemetrexed and pembrolizumab is particularly effective for adenocarcinoma histology, as recommended by the American Society of Clinical Oncology (ASCO) 1